Literature DB >> 12540902

Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders.

Ivelisse Sánchez1, Christian Mahlke, Junying Yuan.   

Abstract

The expansion of a CAG repeat coding for polyglutamine in otherwise unrelated gene products is central to eight neurodegenerative disorders including Huntington's disease. It has been well documented that expanded polyglutamine fragments, cleaved from their respective full-length proteins, form microscopically visible aggregates in affected individuals and in transgenic mice. The contribution of polyglutamine oligomers to neurodegeneration, however, is controversial. The azo-dye Congo red binds preferentially to beta-sheets containing amyloid fibrils and can specifically inhibit oligomerization and disrupt preformed oligomers. Here we show that inhibition of polyglutamine oligomerization by Congo red prevents ATP depletion and caspase activation, preserves normal cellular protein synthesis and degradation functions, and promotes the clearance of expanded polyglutamine repeats in vivo and in vitro. Infusion of Congo red into a transgenic mouse model of Huntington's disease, well after the onset of symptoms, promotes the clearance of expanded repeats in vivo and exerts marked protective effects on survival, weight loss and motor function. We conclude that oligomerization is a crucial determinant in the biochemical properties of expanded polyglutamine that are central to their chronic cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12540902     DOI: 10.1038/nature01301

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  142 in total

1.  A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila.

Authors:  Barbara L Apostol; Alexsey Kazantsev; Simona Raffioni; Katalin Illes; Judit Pallos; Laszlo Bodai; Natalia Slepko; James E Bear; Frank B Gertler; Steven Hersch; David E Housman; J Lawrence Marsh; Leslie Michels Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-01       Impact factor: 11.205

2.  Targeting expression of expanded polyglutamine proteins to the endoplasmic reticulum or mitochondria prevents their aggregation.

Authors:  Erwann Rousseau; Benjamin Dehay; Léa Ben-Haïem; Yvon Trottier; Michel Morange; Anne Bertolotti
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

3.  Inefficient degradation of truncated polyglutamine proteins by the proteasome.

Authors:  Carina I Holmberg; Kristine E Staniszewski; Kwame N Mensah; Andreas Matouschek; Richard I Morimoto
Journal:  EMBO J       Date:  2004-10-07       Impact factor: 11.598

4.  Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of Huntington's disease.

Authors:  Xuesong Chen; Jun Wu; Yuan Luo; Xia Liang; Charlene Supnet; Mee Whi Kim; Gregor P Lotz; Guocheng Yang; Paul J Muchowski; Thomas Kodadek; Ilya Bezprozvanny
Journal:  Chem Biol       Date:  2011-09-23

5.  Human cytomegalovirus UL97 kinase prevents the deposition of mutant protein aggregates in cellular models of Huntington's disease and ataxia.

Authors:  Cristy Tower; Lianwu Fu; Rachel Gill; Mark Prichard; Mathieu Lesort; Elizabeth Sztul
Journal:  Neurobiol Dis       Date:  2010-08-20       Impact factor: 5.996

6.  Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment.

Authors:  Juliette Gafni; Theodora Papanikolaou; Francesco Degiacomo; Jennifer Holcomb; Sylvia Chen; Liliana Menalled; Andrea Kudwa; Jon Fitzpatrick; Sam Miller; Sylvie Ramboz; Pasi I Tuunanen; Kimmo K Lehtimäki; X William Yang; Larry Park; Seung Kwak; David Howland; Hyunsun Park; Lisa M Ellerby
Journal:  J Neurosci       Date:  2012-05-30       Impact factor: 6.167

Review 7.  Regulation of proteasome activity in health and disease.

Authors:  Marion Schmidt; Daniel Finley
Journal:  Biochim Biophys Acta       Date:  2013-08-27

8.  Inhibition of Aggregation of Mutant Huntingtin by Nucleic Acid Aptamers In Vitro and in a Yeast Model of Huntington's Disease.

Authors:  Rajeev K Chaudhary; Kinjal A Patel; Milan K Patel; Radha H Joshi; Ipsita Roy
Journal:  Mol Ther       Date:  2015-08-27       Impact factor: 11.454

Review 9.  A novel therapeutic strategy for polyglutamine diseases by stabilizing aggregation-prone proteins with small molecules.

Authors:  Motomasa Tanaka; Yoko Machida; Nobuyuki Nukina
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

10.  Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.

Authors:  William J Wolfgang; Todd W Miller; Jack M Webster; James S Huston; Leslie M Thompson; J Lawrence Marsh; Anne Messer
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.